Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Objective To determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on triglyceride (TG) levels and insulin resistance in patients with type 2 diabetes. Research design and methods A randomized, double-blind, placebo-controlled trial was performed in 15 adult patients with type 2 diabetes (HbA1c >7.5% [58 mmol/mol]) and hypertriglyceridemia (TG >200 and Results Treatment with volanesorsen significantly reduced plasma apoC-III (-88%, P = 0.02) and TG (-69%, P = 0.02) levels and raised HDL cholesterol (HDL-C) (42%, P = 0.03) compared with placebo. These changes were accompanied by a 57% improvement in whole-body insulin sensitivity (P Conclusions Volanesorsen reduced plasma apoC-III and TG while raising HDL-C levels. Importantly, glucose disposal, insulin sensitivity, and integrative markers of diabetes also improved in these patients after short-term treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The COMPASS trial, which evaluated volanesorsen in patients with multifactorial chylomicronemia (with partial LPL activity), similarly demonstrated substantial TG reductions (~ 71%) and improved metabolic parameters, broadening the potential utility of apoC-III inhibition beyond the rare FCS population.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [47]
In the citing paper
“In addition to TG lowering, volanesorsen has been shown to reduce apoC-III by ~ 80–88% and increase HDL-C by ~ 42% compared with placebo [45–47].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [47]
In the citing paper
“This correlated with >80% reductions in apo C-III, favourable changes across multiple lipoprotein species, unchanged LDL-C and improved carbohydrate metabolism.69–71”
From Clinical review on triglycerides (2020) · cites this paper as [70]
In the citing paper
“In the liver, nicotinic acid inhibits diacylglycerol acyltransferase2 resulting in decreased secretion of VLDL particles, which is also reflected in reductions of plasma levels of both IDL and LDL particles [335].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [335]
In the citing paper
“Nicotinic acid primarily raises HDL-C and ApoA1 by stimulating ApoA1 production in the liver [335].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [335]
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,358
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919 · cited 1×
“Two recent Mendelian randomization studies showed that individuals with loss-of-function APOC3 variants had lower TG concentrations and LDL-C, higher HDL-C, and, compellingly, a 40% reduction in risk of coronary heart disease (15,16).”
BackgroundESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationWu, L., & Parhofer, K. G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.08.010 · Cited by 516
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“On the other, agents that enhance catabolism of TG-rich lipoproteins, such as the antisense oligonucleotide to ApoC-III, and which lead to a concomitant reduction in TGs ( 70%) and a marked elevation in HDL-C ( 40%) in hypertriglyceridemia, are under development.(351) Importantly, however, we currently lack understand…”
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationAntisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Self-citationChemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
“Clinical trials have revealed decreased ApoC-III levels, reducing cardiovascular risk and improving insulin sensitivity (141,142).”
BackgroundClinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“Volanesorsen has also been shown to successfully improved diabetic dyslipidaemia by reducing both apoC-III (−88%) and plasma TG (−69%) in 15 overweight or obese subjects with type 2 diabetes (144).”
BackgroundLipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“In 15 adults with type 2 diabetes mellitus and hypertriglyceridemia treated for 15 weeks, volanesorsen reduced TG by 69%, with significant improvements in glycemia, glucose disposal, and insulin sensitivity.(128) In a study of 17 hypertriglyceridemic patients, volanesorsen significantly reduced TG, apo C-II, and apo C…”
BackgroundAraki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164
“ApoCIII antisense improved insulin sensitivity (39).”
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 155
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 153
Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes
Kanter, J. E., Shao, B., Kramer, F., Barnhart, S., Shimizu-Albergine, M., Vaisar, T., Graham, M. J., Crooke, R. M., Manuel, C. R., Haeusler, R. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127308 · Cited by 105
“The inability of Apoc3 ASO to increase HDL might be due to the lack of cholesteryl ester transfer protein in rodents (37), as antisense inhibition of APOC3 increases HDL levels concomitantly with TG lowering in humans (38, 39).”
BackgroundSelf-citationAntisense drug discovery and development technology considered in a pharmacological context
Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 115
Self-citationEmerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
Taskinen, M.-R., Packard, C. J., & Borén, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0791-9 · Cited by 103
A new dawn for managing dyslipidemias: The era of rna-based therapies
Macchi, C., Sirtori, C. R., Corsini, A., Santos, R. D., Watts, G. F., & Ruscica, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104413 · Cited by 94
“Conversely, HDL-C was raised by 42% (101).”
Kinetics of plasma triglycerides in abdominal obesity
Björnson, E., Adiels, M., Taskinen, M., & Borén, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000375 · Cited by 105
Familial Chylomicronemia Syndrome: A Clinical Guide for Endocrinologists
Falko, J. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0157 · Cited by 93
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Sniderman, A. D., Couture, P., Martin, S. S., DeGraaf, J., Lawler, P. R., Cromwell, W. C., Wilkins, J. T., & Thanassoulis, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082271 · Cited by 92
“Plasma apoB was lowered, but not significantly (58).”
BackgroundRNA Therapeutics in Cardiovascular Precision Medicine
Laina, A., Gatsiou, A., Georgiopoulos, G., Stamatelopoulos, K., & Stellos, K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00953 · Cited by 88
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 98
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
Ginsberg, H. N., & Goldberg, I. J. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317966 · Cited by 80
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
Khan, A. W., & Jandeleit-Dahm, K. A. M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01115-w · Cited by 106
“In patients with type 2 diabetes, volanesorsen significantly reduced fasting plasma APOC3 concentrations and triglyceride levels and improved insulin sensitivity and glucose control compared with placebo 148 .”
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism
Giammanco, A., Spina, R., Cefalu, A. B., & Averna, M. R. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01080-8 · Cited by 94
In vivo and in vitro studies of antisense oligonucleotides – a review
Kilanowska, A., & Studzińska, S. (2020) · RSC Advances · doi:10.1039/d0ra04978f · Cited by 87
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Giglio, R. V., Sasso, B. L., Agnello, L., Bivona, G., Maniscalco, R., Ligi, D., Mannello, F., & Ciaccio, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113634 · Cited by 81
“A randomized, double-blind, placebo-controlled study was conducted in adult patients with T2DM and hypertriglyceridemia treated with metformin and volanesorsen, respectively [74].”
BackgroundMethodLipodystrophy: A paradigm for understanding the consequences of "overloading" adipose tissue
Lim, K., Haider, A., Adams, C., Sleigh, A., & Savage, D. B. (2020) · Physiological Reviews · doi:10.1152/physrev.00032.2020 · Cited by 110
Conservative management in hypertriglyceridemia-associated pancreatitis
Berberich, A. J., Ziada, A., Zou, G. Y., & Hegele, R. A. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12925 · Cited by 67
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Gupta, M., Blumenthal, C., Chatterjee, S., Bandyopadhyay, D., Jain, V., Lavie, C. J., Virani, S. S., Ray, K. K., Aronow, W. S., & Ghosh, R. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764937 · Cited by 74
“tions of this drug in other conditions including familial partial lipodystrophy [55].”
BackgroundResultEmerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
Geldenhuys, W. J., Lin, L., Darvesh, A. S., & Sadana, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.007 · Cited by 64
“In a recent report, the efficacy of volanesorsen in improving insulin sensitivity was demonstrated in type 2 diabetes patients [136].”
Nutter, C. A., & Kuyumcu‐Martinez, M. N. (2017) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1459 · Cited by 69
“There are two completed clinical trials that used ASOs to improve insulin sensitivity and decrease dyslipidemia in diabetic patients (Digenio et al., 2016; van Dongen et al., 2015).”
BackgroundExploring apolipoprotein C-III: pathophysiological and pharmacological relevance
Packard, C. J., Pirillo, A., Tsimikas, S., Ference, B. A., & Catapano, A. L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvad177 · Cited by 61
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 62
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 70
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 75
Updates in Drug Treatment of Severe Hypertriglyceridemia
Gouni-Berthold, I., Schwarz, J., & Berthold, H. K. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01140-z · Cited by 59
“Volanesorsen has also been evaluated in other conditions associated with sHTG such as diabetes mellitus type 2 ( N = 15, 15-week phase 2 study) [16] and familial partial lipodystrophy (FPL) ( N = 40, 13-week phase 2/3 study), the BROADEN study [17].”
BackgroundNew Therapies for Primary Hyperlipidemia
Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab876 · Cited by 57
Rocha, N. A., East, C., Zhang, J., & McCullough, P. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0697-3 · Cited by 54
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies
Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P. K., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052196 · Cited by 71
“Another promising RNA-based therapy is volanesorsen, a GalNAc-conjugated ASO targeting APOC3 mRNA [137].”
High Density Lipoproteins and Diabetes
Cochran, B. J., Ong, K. L., Manandhar, B., & Rye, K. (2021) · Cells · doi:10.3390/cells10040850 · Cited by 61
“Indirect evidence that apoC-III may be causally related to the development of diabetes was obtained from a small randomised, double-blind, placebo-controlled clinical trial of patients with T2D in which treatment with an apoC-III antisense oligonucleotide that reduced plasma apoC-III levels by 88% increased HDL-C leve…”
BackgroundApoCIII: A multifaceted protein in cardiometabolic disease
D'Erasmo, L., Di Costanzo, A., Gallo, A., Bruckert, E., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 50
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 56
RNA Therapeutics: How Far Have We Gone?
Coutinho, M. F., Matos, L., Santos, J. I., & Alves, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-19966-1_7 · Cited by 52
Wang, H., Huang, X., Xu, P., Liu, X., Zhou, Z., Wang, F., Li, J., Wang, Y., Xian, X., Liu, C., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154740 · Cited by 43
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 47
Botteri, G., Montori-Grau, M., Gumà, A., Pizarro‐Delgado, J., Cedó, L., Escolá‐Gil, J. C., Li, D., Barroso, E., Palomer, X., Kohan, A. B., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4401-5 · Cited by 44
Advances in Phenotyping Obesity and in Its Dietary and Pharmacological Treatment: A Narrative Review
Pujia, R., Tarsitano, M. G., Arturi, F., LORENZO, A. D., Lenzi, A., Pujia, A., & Montalcini, T. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.804719 · Cited by 45
“Volanesorsen is a secondgeneration chimeric antisense therapeutic oligonucleotide (ASO) which selectively reduces apoC3 mRNA, thereby lowering the levels of triglycerides and FM in particular genetic syndromes such as familial partial lipodystrophy (139, 140).”
BackgroundTreatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
Fogacci, F., Norata, G. D., Toth, P. P., Arca, M., & Cicero, A. F. G. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00836-w · Cited by 42
“…and outcome assessment Incomplete outcome data Selective outcome reporting Other potential threats to validity Witztum, 2019 [28••] L L L H H L Digenio, 2016 [29] L L L H H U Gaudet, 2015 [30] L L L H H U H, high risk of bias; L, low risk of bias; U, unclear risk of bias ed the key role…”
BackgroundQuartet of APOCs and the Different Roles They Play in Diabetes
Hsu, C.-C., Kanter, J. E., Kothari, V. M., & Bornfeldt, K. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318290 · Cited by 42
The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.003 · Cited by 42
“[70] performed a randomized , double-blind, placebo-controlled trial in patients with type 2 diabetes (N=15) and h ypertriglyceridemia, the latter defined as triglycerides ranging between 200-500 mg/dL.”
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
“ApoCIII inhibition by volanesorsen reduced plasma concentrations of apoCII, apoCIII, and TG, without affecting concentrations of apoB100.(149,159,160) Whether targeting of apoCIII in patients with elevated concentrations of TRLs will reduce risk of CVD is subject of ongoing studies, but a recent report on the use of v…”
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
Nurmohamed, N. S., Dallinga‐Thie, G. M., & Stroes, E. S. G. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1768848 · Cited by 43
“comparable apoC-III and TG reductions [61].”
Calcaterra, I., Lupoli, R., Di Minno, A., & Di Minno, M. N. D. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13841 · Cited by 37
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Shemesh, E., & Zafrir, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188856 · Cited by 45
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 46
Targeting angiotensinogen with RNA-based therapeutics
Ren, L., Colafella, K. M. M., Bovée, D. M., Uijl, E., & Danser, A. H. J. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000586 · Cited by 40
Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
Dib, I., Khalil, A., Chouaib, R., El-Makhour, Y., & Noureddine, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06071-5 · Cited by 40
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 35
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 46
Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
Kolovou, G., Kolovou, V., & Katsiki, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040982 · Cited by 33
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
“lencing apoC-III activity via antisense therapy lowered TRLs in diabetic [113] and non-”
BackgroundAntisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes
Chen, S., Sbuh, N., & Veedu, R. N. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0891 · Cited by 30
Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes
Croyal, M., Wargny, M., Chemello, K., Chevalier, C., Blanchard, V., Bigot‐Corbel, E., Lambert, G. C., May, C. L., Hadjadj, S., & Cariou, B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01452-5 · Cited by 34
“mRNA, improves insulin sensitivity and reduces HbA1C in patients with T2D [28].”
BackgroundLightbourne, M., Startzell, M. S., Bruce, K. D., Brite, B., Muniyappa, R., Skarulis, M. C., Shamburek, R. D., Gharib, A. M., Ouwerkerk, R., Walter, M. F., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.06.011 · Cited by 27
Vyletelová, V., Nováková, M., & Pašková, Ľ. (2022) · Pharmaceuticals · doi:10.3390/ph15101278 · Cited by 30
Spagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 28
Apolipoprotein CIII is a new player in diabetes
Juntti‐Berggren, L., & Berggren, P. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000372 · Cited by 30
Akivis, Y., Alkaissi, H. R., McFarlane, S. I., & Bukharovich, I. F. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x272750240109052319 · Cited by 34
“In the COMPASS trial, patients with severe hypertriglyceridemia showed a mean reduction of about 71% [61].”
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 30
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
“reduced plasma apoCIII and triglyceride levels and increased HDL-C levels, and this was associated with an improvement in insulin sensitivity [133].”
BackgroundVolanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 26
Monocyte and macrophage foam cells in diabetes-accelerated atherosclerosis
Cervantes, J., & Kanter, J. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1213177 · Cited by 27
“For example, antisense oligonucleotide-mediated suppression of APOC3 resulted in an almost 70% reduction in plasma triglycerides in people with type 2 diabetes (77).”
BackgroundD’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 25
Vahdat‐Lasemi, F., Mahjoubin‐Tehran, M., Aghaee‐Bakhtiari, S. H., Jalili, A., Jaafari, M. R., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.007 · Cited by 24
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan, D. C., & Watts, G. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000920 · Cited by 24
Kounatidis, D. C., Tentolouris, N., Vallianou, N. G., Mourouzis, I. S., Karampela, Ι., Stratigou, T., Rebelos, E., Kouveletsou, M., Stamatopoulos, V., Tsaroucha, E., et al. (2024) · Metabolites · doi:10.3390/metabo14070388 · Cited by 26
“Additionally, volanesorsen has shown promise in improving glucose profiles in individuals with T2DM, as it has been reported to enhance glucose disposal, insulin resistance, and hepatic steatosis in these subjects [379,380].”
BackgroundThe Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease
Bornfeldt, K. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317163 · Cited by 23
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 29
“The antisense therapeutic oligonucleotides have also been shown to markedly lower plasma apoC-III and triglycerides levels in subjects with severe or uncontrolled hypertriglyceridemia (Gaudet et al. 2015; Gouni-Berthold 2017) and in subjects with diabetic dyslipidemia (Digenio et al. 2016).”
BackgroundYoo, M., Kim, H., Jang, H., Lee, H., & Park, S. G. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13111133 · Cited by 22
“A recent randomized controlled trial reported that reduced TG concentrations were significantly associated with improved insulin sensitivity [26].”
BackgroundApolipoprotein CIII and diabetes. Is there a link?
Christopoulou, E. C., Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3118 · Cited by 22
“Inhibitors of ApoCIII reduced plasma ApoCIII and TRG and improved insulin sensitivity and plasma glucose control.(62) Thus, targeting ApoCIII might consist a novel treatment that will expand the current repertoire of antidiabetic agents.”
BackgroundPan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
New approaches to address dyslipidemia
Parhofer, K. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000456 · Cited by 20
Buckner, T., Shao, B., Eckel, R. H., Heinecke, J. W., Bornfeldt, K., & Snell‐Bergeon, J. K. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.10.006 · Cited by 20
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Rastogi, A., Dunbar, R. L., Thacker, H. P., Bhatt, J. K., Parmar, K., & Parmar, D. V. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01487-8 · Cited by 21
Self-citationA Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 20
“Another important finding was that volanesorsen was equally efficacious in lowering triglycerides in patients both taking and not taking lipid-lowering treatments, including fibrates, statins and fish oils [88].”
BackgroundFeingold, K. R. (2017) · Europe PMC (PubMed Central) · Cited by 18
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
Sigfrids, F. J., Stechemesser, L., Dahlström, E. H., Forsblom, C. M., Harjutsalo, V., Weitgasser, R., Taskinen, M., Groop, P., & the FinnDiane Study Group (2021) · Journal of Internal Medicine · doi:10.1111/joim.13412 · Cited by 19
Milonas, D., & Τζιόμαλος, Κ. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582028 · Cited by 17
Joint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
de Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 16
Recent Apolipoprotein CIII trials
Tramontano, D., Bini, S., D’Erasmo, L., & Arca, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000849 · Cited by 14
Florentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
Metadata
- Authors
- Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., Baker, B. F., Bhanot, S., & Crooke, R. M.
- Affiliations
- Akcea Therapeutics, Cambridge, MA
- University of Pennsylvania (US)
- Ionis Pharmaceuticals (United States) (US)
- Profil Institute for Clinical Research (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-06
- Volume
- 39
- Issue
- 8
- Pages
- 1408-1415
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2418001336
- Cited by
- 170
- References
- 41
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 16 · 2023: 16 · 2022: 18 · 2021: 18 · 2020: 19 · 2019: 23 · 2018: 13 · 2017: 14 · 2016: 7
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- volanesorsen, apolipoprotein C-III, antisense oligonucleotides, type 2 diabetes, hypertriglyceridemia, insulin sensitivity, insulin resistance, triglycerides, HDL cholesterol, glycated albumin, fructosamine, glycemic control, glucose disposal
- MeSH terms
- Aged, Anticholesteremic Agents, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Hypertriglyceridemia, Biomarkers, Oligonucleotides, Antisense, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.